Spine Align Raises $1.75M Series Seed Round

September 14, 2020

Spine Align, LLC, a medical device company developing a portfolio of products that enable spine surgeons to measure, visualize, and adjust patients’ spinal alignment during surgery, recently closed a $1.75M Series Seed round.

Spine Align reports the financing is led by the Rockies Venture Club, with additional support by members of the Berkeley Angel Network, NO/LA Angel Network, Pasadena Angels, Bellingham Angels, the Abell Foundation, and VentureWell. This round supports development efforts to achieve FDA 510(k) clearance for their flagship product, LiveAlignTM, in 2021.

“This milestone is a culmination of years of tireless work by our team to build an innovative platform of products that rethink what’s possible for spine surgeons today. We could not be more grateful to our investor partners, medical and business advisory board members, and engineering team to bring us to where we are today and where we are heading,” said Amir Soltanianzadeh, CEO & Co-Founder.

“The solution that Spine Align has developed will have a dramatic impact on spinal surgery. Rockies Venture Club was proud to lead this funding round and found that many investors across the country saw the same potential in the company,” added Dave Harris, Director of Operations at Rockies Venture Club.

“This funding round represents a tremendous milestone of being closer to positively impacting the lives of patients with our technology. LiveAlignTM is just the first of many products in our portfolio that will seamlessly augment the art of surgery with digital feedback,” said Dr. David Gullotti, CTO & Co-Founder.

“The Spine Align platform leverages the infrastructure of image-guided and robotic technologies to deliver the next generation of surgery. My colleagues and I cannot wait to use this breakthrough technology in the operating room next year,” said Dr. Nicholas Theodore, Co-Founder of Spine Align and Director of the Neurological Spine Program at the Johns Hopkins Hospital.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”